Autolus Therapeutics Ltd – (NASDAQ:AUTL)’s share price was up 5.1% during trading on Wednesday . The stock traded as high as $10.76 and last traded at $10.54, approximately 212,747 shares changed hands during trading. An increase of 115% from the average daily volume of 98,845 shares. The stock had previously closed at $10.03.
Several analysts recently commented on AUTL shares. Zacks Investment Research raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. ValuEngine raised Autolus Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $41.00 target price (down from $45.00) on shares of Autolus Therapeutics in a report on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $45.50.
The company has a market capitalization of $395.48 million, a PE ratio of -7.42 and a beta of 0.40. The stock has a fifty day moving average price of $14.79. The company has a quick ratio of 10.66, a current ratio of 10.66 and a debt-to-equity ratio of 0.12.
Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.11. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $2.00 million. Sell-side analysts predict that Autolus Therapeutics Ltd – will post -3.07 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Exane Derivatives acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $50,000. Virtus ETF Advisers LLC grew its holdings in Autolus Therapeutics by 105.3% in the second quarter. Virtus ETF Advisers LLC now owns 17,311 shares of the company’s stock valued at $279,000 after purchasing an additional 8,877 shares during the period. Geode Capital Management LLC acquired a new stake in Autolus Therapeutics in the fourth quarter valued at approximately $322,000. CWM LLC grew its holdings in Autolus Therapeutics by 29.3% in the second quarter. CWM LLC now owns 45,384 shares of the company’s stock valued at $731,000 after purchasing an additional 10,274 shares during the period. Finally, TD Asset Management Inc. grew its holdings in Autolus Therapeutics by 101.2% in the second quarter. TD Asset Management Inc. now owns 21,229 shares of the company’s stock valued at $342,000 after purchasing an additional 10,680 shares during the period. 43.43% of the stock is currently owned by institutional investors.
Autolus Therapeutics Company Profile (NASDAQ:AUTL)
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.